Ivabradine Xiromed

Active Ingredient:: Ivabradine
Origin:: EU

Ivabradine Xiromed (Ivabradine)

Q: Who should not use Ivabradine Xiromed?

Ivabradine should not be used in patients with severe hepatic impairment, sick sinus syndrome, a resting heart rate below 50 bpm, acute decompensated heart failure, or in those taking strong CYP3A4 inhibitors that cannot be discontinued. Contraindications are detailed in the product’s prescribing information.

Ivabradine, the active ingredient in Ivabradine Xiromed, is a If channel inhibitor presented as an oral tablet for oral use. It reduces heart rate and is used to manage chronic stable angina and heart failure in adult patients.

GNH India supplies Ivabradine Xiromed as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards, provides regulatory‑compliant documentation for global distribution, and ensures products are manufactured under GMP conditions with rigorous quality testing before release.

Manufacturer / TM Owner

Medical Valley Invest Ab

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Ivabradine is indicated for conditions where reduction of heart rate improves clinical outcomes, primarily within the cardiovascular disease spectrum.

Chronic stable angina: improves exercise tolerance and reduces the frequency of angina attacks.
Heart failure with reduced ejection fraction (NYHA class II‑III): lowers heart rate, decreasing myocardial oxygen demand and supporting symptom control.
Angina pectoris in patients who cannot tolerate beta‑blockers: provides heart‑rate reduction without affecting contractility.

How It Works

Ivabradine selectively inhibits the funny (If) current in the sinoatrial node, which slows the spontaneous depolarization of pacemaker cells. By reducing the slope of phase 4 depolarization, the drug lowers resting heart rate without altering myocardial contractility, ventricular repolarization, or blood pressure, thereby decreasing cardiac oxygen consumption.

Side Effects

Adverse reactions may range from mild to serious and should be monitored during therapy.

Common Side Effects

Visual disturbances (phosphenes): transient luminous phenomena.
Bradycardia: resting heart rate below 50 bpm.
Headache.
Dizziness.
Fatigue.
Blurred vision.

Serious or Rare Side Effects

Symptomatic bradycardia requiring medical intervention.
Atrial fibrillation or other serious arrhythmias.
Severe visual disturbances, including persistent luminous phenomena.
Hypotension.
Hepatic injury.
Allergic reactions such as rash or angioedema.

Precautions & Warnings

Before initiating therapy, clinicians should assess patient suitability and monitor for specific risks.

Heart rate monitoring: ensure resting heart rate >50 bpm before starting.
Hepatic function: avoid or adjust in severe hepatic impairment.
Sick sinus syndrome: contraindicated in patients with this condition.
Concomitant bradycardic agents: use with caution when combined with beta‑blockers or digoxin.
Renal impairment: dose adjustment may be required in moderate to severe renal dysfunction.
Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Avoid Interactions

Ivabradine may interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma concentrations.
Other bradycardic agents (beta‑blockers, digoxin, non‑dihydropyridine calcium channel blockers): risk of excessive heart‑rate reduction.
Verapamil or diltiazem: potentiate bradycardia.
Other If channel inhibitors: additive effect on heart rate.

Moderate Interactions (Monitor Closely)

CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy.
Antihypertensive agents: monitor blood pressure and heart rate.
Diuretics: watch for electrolyte disturbances that could affect cardiac conduction.

Frequently Asked Questions

Ivabradine Xiromed is used to lower heart rate in adults with chronic stable angina and in patients with heart failure with reduced ejection fraction (NYHA class II‑III). By reducing the heart rate, it helps relieve angina symptoms and improves functional capacity in heart‑failure patients.

Ivabradine works by selectively blocking the funny (If) current in the sinoatrial node. This inhibition slows the spontaneous depolarisation of pacemaker cells, leading to a reduction in resting heart rate without affecting myocardial contractility, blood pressure, or ventricular repolarisation.

The dosage of Ivabradine Xiromed is individualized by the prescribing clinician based on the patient’s heart‑rate, clinical condition, and tolerability. The prescriber determines the appropriate starting dose and any subsequent titration according to current clinical guidelines.

Safety data for Ivabradine in pregnancy and lactation are limited. It should only be used when the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details and any required import documentation.

Both Ivabradine and beta‑blockers lower heart rate, but they act via different mechanisms. Beta‑blockers reduce heart rate by blocking adrenergic receptors and also lower blood pressure and contractility, whereas Ivabradine selectively inhibits the If current without affecting contractility or blood pressure. Ivabradine is often considered when beta‑blockers are contraindicated or not tolerated.

Store Ivabradine Xiromed at room temperature, below 25 °C. Keep the tablets in the original container, protect them from moisture and direct sunlight, and ensure they are out of reach of children.

Ivabradine Xiromed is taken orally as a tablet. The tablet should be swallowed whole with a glass of water, with or without food, as directed by the prescribing physician.

The most serious risks include symptomatic bradycardia (resting heart rate <50 bpm), atrial fibrillation or other serious arrhythmias, and severe visual disturbances such as persistent luminous phenomena. Patients should be monitored regularly for these events, and therapy should be discontinued if they occur.

Ivabradine should not be used in patients with severe hepatic impairment, sick sinus syndrome, a resting heart rate below 50 bpm, acute decompensated heart failure, or in those taking strong CYP3A4 inhibitors that cannot be discontinued. Contraindications are detailed in the product’s prescribing information.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 14 Aug 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.